Focusing on in-vitro diagnostics and being China’s POCT leader, Wondfo always strives to make breakthrough innovations to push the boundaries of technologies in this area. 

Our R&D Srength

Our annual investment to R&D accounts for over 10% of sales revenue, 1.6 times larger that the industry average, and continues to grow year on year.

Currently, we have an R&D team of 532 employees professional in biochemistry, clinical medicine, microelectronics technology, and have built R&D centers in China (Guangzhou, Hangzhou), and the United States (San Diego). 

Besides, we build laboratories in cooperation with a number of key universities, further strengthing our R&D capacity. 
                              



Our R&D Achievements

With stronger R&D capacity and relentless efforts to R&D,  Wondfo has already got 226 authorized patents, 172 trade marks registered in China, 113 registede in overseas countries, 189 NMPA, 162 CE, 69 510(K) clearances, 3 Health Canada MDLL.



We will continue to deliver more comprehensive and effective solutions in diagnostic testing, and to provide health care facilities worldwide with high-quality, safe, and more cost-effective products that help improve diagnostics efficiency and the effective of treatment monitoring.

It’s our passion and commitment to save lives and promote public health with top-of-the-line products and services.
 

Reliablity and excellence in quality is paramount in everything we do. We own GMP Standard and 100,000 class cleanrooms to ensure the safety and hygiene of our products.

We strictly implement ISO-9001:2008 and ISO13485 Quality Management System and follow the standards and regulations of WHO, EU, FDA, etc., to ensure that every product out of our factory meet the expectation of our customers worldwide.  Our products are extensively recognized by many national and international awards and certifications, such as the National Science and Technology Progress Award, WHO Prequalification, and AEO by WCO.